Jia-Xin Cao Selected Research

pelcitoclax

1/2021

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jia-Xin Cao Research Topics

Disease

2	Neoplasms (Cancer) 10/2022 - 09/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 09/2021
1	Nasopharyngeal Carcinoma 01/2021

Drug/Important Bio-Agent (IBA)

1	AntibodiesIBA 10/2022
1	Granzymes (Granzyme)IBA 10/2022
1	2- amino- 3- (4'- N,N- bis(2- chloroethyl)amino)phenylpropionic acid N-oxideIBA 10/2022
1	Immune Checkpoint InhibitorsIBA 10/2022
1	LipidsIBA 09/2021
1	HDL CholesterolIBA 09/2021
1	Gemcitabine FDA Link 01/2021
1	pelcitoclaxIBA 01/2021

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 09/2021 - 01/2021
1	Adjuvant Chemotherapy 09/2021